1例前列腺癌患者随访10年报道及文献复习

doi:10.19558/j.cnki.10-1020/r.2022.02.009

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1045 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的：探究1例盆腔淋巴结转移高危前列腺癌患者联合根治术、术前辅助及术后辅助内分泌治疗后的临床疗效。方法：回顾性分析1例盆腔淋巴结转移高危前列腺癌患者,经术前辅助内分泌治疗、前列腺癌根治术、术后辅助内分泌治疗,7年后进展为去势抵抗前列腺癌,后改用阿比特龙联合泼尼松/地塞米松治疗,并随访PSA、临床症状体征及不良反应。结果：术后辅助内分泌治疗维持87个月至mCRPC,阿比特龙治疗25个月至耐药,患者临床无症状生存10年,一般状况良好。结论：盆腔淋巴结转移高危前列腺癌患者或可从以根治术为基础的术前、术后辅助内分泌治疗中增加生存获益,延缓进展至mCRPC。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	胡恩平
	潘正波
	季广华
	师冠云

关键词 ：淋巴结转移, 根治术, 内分泌治疗, 转移去势抵抗性前列腺癌

Abstract：Objective： To explore the clinical effect of combined radical prostatectomy, neoadjuvant therapy and adjuvant endocrine therapy in 1 case of high-risk prostate cancer with pelvic lymph node metastasis. Methods： A case of high-risk prostate cancer with pelvic lymph node metastasis was analyzed retrospectively. After 7 years of sequential neoadjuvant endocrine therapy, radical prostatectomy and adjuvant endocrine therapy, it developed castration resistance to prostate cancer （CRPC）. It was treated with abiraterone combined with prednisone/dexamethasone. PSA, clinical symptoms, signs, and adverse reactions were followed up. Results： Postoperative adjuvant endocrine therapy was maintained from 87 months to metastatic CRPC （mCRPC） and abiraterone treatment from 25 months to drug resistance. The patients survived asymptomatic for 10 years and had good physical fitness. Conclusion： Patients with prostate cancer at high risk of pelvic lymph node metastasis may be able to delay progression to mCRPC from neoadjuvant, adjuvant endocrine therapy based on radical surgery. The new endocrine therapy can increase the benefit of clinical asymptomatic survival.

Key words： pelvic lymph node metastasis radical prostatectomy endocrine therapy metastatic castration-resistant prostate cancer

收稿日期: 2021-12-09

通讯作者: 胡恩平, enpinghu@163.com

引用本文:

胡恩平, 潘正波, 季广华, 师冠云. 1例前列腺癌患者随访10年报道及文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 112-116.
Hu Enping, Pan Zhengbo, Ji Guanghua, Shi Guanyun. 10-year follow-up of a patient with prostate cancer: Case report and literature review. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2022, 11(2): 112-116.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1756.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2022/V11/I2/112

[1] LIN G W, LI G X, DAI B, et al.Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer[J]. Asian J Androl,2019,21(2):131-136.
[2] GEORGE D J, SARTOR O, MILLER K, et al.Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States[J]. Clin Genitourin Cancer,2020,18(4):284-294.
[3] UEMURA H, YE D, KANESVARAN R, et al.United in Fight against prostate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia.[J] BJU Int,2020,125(4):541-552.
[4] DING W, YE H, GAO X. Preliminary results of China M1 cases from a large, multi-center, prospective, longitudinal cohort study in China[Z]. Presented by Prof Gao Xin at 2018 CACA GU annual conference, Dec 8,2018.
[5] Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group[J]. Lancet,2000,355(9214):1491-1498.
[6] AURILIO G, CIMADAMORE A, SANTONI M, et al.New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents[J]? Cells,2020,9(6):1522.
[7] 董柏君,樊连城,薛蔚.转移性去势抵抗性前列腺癌诊治新进展[J].中华泌尿外科杂志,2017,38(z1):6-10.
[8] 薛文彬,杨璐,黄煜,等.转移性去势抵抗性前列腺癌的早期诊断及治疗[J].中华泌尿外科杂志,2018,(Z1):1-4.
[9] RYAN C J, SMITH M R, FIZAZI K, et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2015,16(2):152-60.
[10] MILLER K, CARLES J, GSCHWEND J E, et al.The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score[J]. Eur Urol,2018,74(1):17-23.
[11] TAN G, XUAN Z, LI Z, et al.The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials[J]. Transl Androl Urol,2020,9(4):1691-1699.
[12] EGGENER S E, SCARDINO P T, WALSH P C, et al.Predicting 15-year prostate cancer specific mortality after radical prostatectomy[J]. J Urol,2011,185(3):869-875.
[13] MCCLINTOCK T R, VON LANDENBERG N, COLE A P, et al.Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status[J]. Ann Surg Oncol, 2019, 26(1): 297-305.
[14] UEDA Y, MATSUBARA N, TABATA K I, et al.Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer[J]. Clin Genitourin Cancer,2017,15(2):320-325.
[15] NISHIMURA K, NONOMURA N, YASUNAGA Y, et al.Low doses of oral dexamethasone for hormone-refractory prostate carcinoma[J]. Cancer, 2000,89(12):2570-2576.
[16] RYAN C J, SMITH M R, DE BONO J S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy[J]. N Engl J Med,2013,368(2):138-148.
[17] NI Y C, ZHAO J G, ZHANG M N, et al.Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cance. Asian J Androl,2022,24(2):154-160.
[18] YANG Z, NI Y, ZHAO D, et al.Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone. BMC cancer,2021,21(1):919.